Clinical Trial Update: A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older [Phase 3]

View source ↗

Summary

Phase 3 study evaluating immune response, safety, and RSV-associated respiratory illness after RSV OA Vaccine in adults aged 60 and older has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• RSV OA vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 3 | Status: COMPLETED